Latest Safety News

Page 4 of 252
Charles River Laboratories delivered a second consecutive quarter of organic revenue growth and raised its 2026 outlook, despite reported revenue falling after divestitures. The quarter’s sharp GAAP earnings increase was heavily amplified by a US$245.6 million tax reserve reversal.
Ada Torres
Ada Torres
4 Nov 2026
Emerson delivered a stronger fiscal 2026 finish, with fourth-quarter sales up 7%, GAAP earnings per share up 24% and free cash flow up 9%. The industrial automation group also raised its dividend and outlined roughly 5% growth for fiscal 2027.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Coast Entertainment has outlined a staged plan to build a four-star hotel and entertainment, dining and retail precinct beside Dreamworld, with preliminary modelling indicating a completion value of about $330 million. The proposal comes as the company returns to profit and reports stronger visitation, cash generation and asset valuations.
Victor Sage
Victor Sage
3 Nov 2026
Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
Ada Torres
2 Nov 2026
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026
Latrobe Magnesium has lifted commissioning progress at its Victorian Phase 1B plant to 50%, with installation now 98% complete. The company continues to target first magnesium metal crowns exceeding 98% purity by the end of 2026, while remaining within its A$6.1 million project budget.
Victor Sage
Victor Sage
2 Nov 2026
Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
Ada Torres
Ada Torres
2 Nov 2026
RBR Group has secured its first post-restart Mozambique LNG contract, but the A$2 million-scale award arrives alongside just A$32,000 in cash and overdue convertible notes. The company is relying on further contract wins, debt restructuring and new capital to bridge the gap.
Victor Sage
Victor Sage
30 Oct 2026
Provaris Energy advanced DNV approval work for its 25,000 cubic metre LCO₂ tank and completed further stages of its hydrogen prototype during the September quarter. The technical progress came alongside a funding push, with $777,000 in cash at quarter-end and an oversubscribed $914,500 share purchase plan completed after the period.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Rand Mining will pay a fully franked 10 cents per share dividend after operating cash flow swung to a A$2.339 million inflow in the September quarter. Gold production reached 2,908 ounces attributable to Rand, although group gold mined fell 11% from the previous quarter.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Cadoux Limited (ASX:CCM) has strengthened the technical case for its high-purity alumina and rare earths portfolio, including battery qualification and new Danube mineralisation beyond its previous exploration envelope. The progress comes with a thinner cash buffer, no listed financing facilities and several commercial milestones still ahead.
Victor Sage
Victor Sage
30 Oct 2026
Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive